potential stage want on to development think current the and pipeline transaction on our market. is of A of our by broader of to expand development in portfolio. pipeline, Thanks, frexalimab stage project our any which strategy. we Instead overview an central want to strong highlight provide we focusing the I Marshall. growing is underappreciated the detail, one
therapies, a in peak development annual are assembled development billion messages. hands and the XX to have the these greater since potential Most therapies stage which contribute potential in we powerful Slide that royalties. of we our In take-home combined short, are of portfolio consists believe have than marketers. blockbusters key IPO, the summarizes XX $X of
therapies carefully in the have development. We our selecting and late-stage of that profile portfolio primarily this product managed risk by which framework meet are
possible. structures built where also deal risk mitigating in have We
events, the see to the FDA for TEV-'XXX we significant and in and the XXXX, regulatory the has of potential next to a through and Lastly, portfolio this Tremfya over KarXT, and value begin study expect we action pivotal for XX for royalty XX These to potential which aficamten exciting expect multiple portfolio. date months. for we clinical data And unlocking FDA and for our seltorexant, be the very pelecarsen, results filings pelabresib outcomes which Crohn's. include
Slide with approved balance to $XX therapies. XXXX, of a stage since development deployed capital billion close XX we that healthy highlights between and have
just been acquire this has the the on towards to deployed IPO. capital of the approved royalties the I case products. Over approved expansion our products majority even And remained pipeline referenced, period, our has since with stage of development weighting our
However, is the in of variability considerable mix, nature which an this on look opportunistic reflects there we annual basis, our when business.
since Slide neurology, immunology. nicely is XX shows June XXXX pipeline we comes strong right-hand fivefold The that it When cancer, IPO. disease pipeline record. our including and side graphic a track rare our the therapies, on grown in development-stage to therapeutic has have development area, psychiatry, cardiology, our stage that diversified illustrates investing by
have investments are has XX, only product on selection you XX% development not have with the that and This record framework billion to, ability $X have patient Approximately spoke reached our market. opportunity Around XX% our stage of Our XX% needs we underserved including Slide can around approval. see unmet Marshall reflects and development in receive therapies to diligence and identify and to large our category this rate that invested high. set. the process, been in our success On regulatory still gone
point, investments. higher To stage on inherent previous target and approach a have on we development my investing. returns Slide we in balance teens for the unique XX, the we versus believe powerful Expanding development-stage risk accrued to products
to are study supported therapies, our the we structure directly regulatory product have data and the of program a clinical then proof-of-concept to to strategies so requiring in receiving product sales also to investing we mitigation Once innovators through strategies have risk partner and These ensure investing, into of few. of and often with transaction correspondence terms due interest strongly in include we selection, strong In milestones our the can a made stage we typically return insights portion we with post-pivotal addition selection, by that additional include and the patient-level access deep potential. data, the aligned and partner. name diligence
our You of frexalimab unique can illustrate investments aficamten, approach, see in here and examples our KarXT, including a Merck-XXXX. that number
slide. to shows -- associated receive. final Slide my XX is could our potential expect pipeline we peak late-stage by and receive the It royalty sales element
individual Based this to Royalty in a Pharma, translate frexalimab The royalty olpasiran the largest over And by potential $XX billion multi-blockbuster peak annual the combined potentially all or the on rates, on nonrisk-adjusted basis. sales billion peak respective $X.XX we potential. these have majority first Importantly, at aggregate, best-in-class could world-class estimate in to are royalty and have over and supported contributors. marketers. with potentially
I of second would olanzapine, forward the efficacy with primary injectable of profile. year. encouraging antipsychotic pleased a additional by safety the achieved that an in continues We look news announced updates Phase the also in the study have version Teva and half that add endpoint TEV-'XXX, long-acting to are to the positive its we III
with As partnered R&D provide of Phase XXXX, funding Pharma a to up TEV-'XXX program. Teva reminder, Royalty fall in the in million to $XXX III for the
as approval mid-single-digit royalties as FDA on payment milestone a well low receive sales. will We on its to
Given products unique again, we its to a to partner safety with the differentiated in unmet market highlights commercial potential significant for across ability This, innovators identify profile attractive our emerging need, about excited are biopharma with the development. industry and accelerate once TEV-'XXX.
the become in As to our commercial, these years contribute they growth ahead. attractive products compounding will
have To years can ahead. so an multiple close, deliver expected continue events to why growth expect to upcoming stage we see portfolio, the exciting attractive you compounding we development with in
I like hand over that, it With would to to Terry.
